Explore Watchlists Pricing

SEIKAGAKU CORPORATION (4548) Income statement

Market cap

¥41.9B

P/E ratio

17.9x

Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.

Summary Financials Dividends History Ownership Workforce

Income statement Balance sheet Cash flow Other

	2012/03	2013/03	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03	2026/03
Revenue	27,082	26,639	29,614	29,522	30,962	29,589	30,175	28,384	28,642	27,662	34,851	33,456	36,213	39,374	36,645
Revenue growth (%)	-
Cost of revenue	-	-	-	12,130	12,871	13,247	13,008	13,114	12,513	12,112	14,323	15,432	19,336	20,221	20,673
Gross profit	-	-	-	17,391	18,091	16,341	17,166	15,270	16,129	15,549	20,528	18,024	16,877	19,153	15,972
Gross margin (%)	-	-	-
Operating margin (%)	-	-	-
Operating expenses	-	-	-	15,008	15,946	15,059	15,745	14,292	14,169	14,018	16,033	15,910	16,444	17,819	16,632
Operating income	-	-	-	2,383	2,144	1,282	1,421	977	1,960	1,530	4,495	2,114	433	1,333	-660
Income before tax	4,770	4,302	5,878	4,008	3,500	2,477	5,327	2,859	3,981	3,024	5,395	3,069	1,691	1,933	1,679
Pretax margin (%)	17.6	16.1	19.8	13.6	11.3	8.4	17.7	10.1	13.9	10.9	15.5	9.2	4.7	4.9	4.6
Provision for income taxes	-	-	-	357	922	689	1,404	614	1,296	-1,237	1,661	832	-495	718	36
Effective tax rate (%)	-	-	-
Net income	2,429	4,032	4,360	3,650	2,578	1,787	3,922	2,244	-10,839	4,262	3,733	2,236	2,186	1,214	737
Earnings per share	57.58	57.33	83.55	64.27	45.39	31.55	69.3	39.76	-192.15	75.54	66.32	40.49	40.08	22.25	26.99
Dividend per share	-	-	-	-	-	-	-	-	26	24	30	26	26	30	30